US company submits data kickstarting approval process with regulators around the world
Final results from the trials of Moderna’s vaccine against Covid-19 confirm it has 94% efficacy and nobody who was vaccinated with it developed severe disease, says the company, kickstarting the approval process with regulators around the world.
The US company is submitting the data to the regulators in the US, Europe and the UK for an emergency licence. It expects the Food and Drug Administration in the US to consider it at its meeting on 17 December, Moderna said.
